The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis

Purpose An open‐label, multiple‐dose, parallel‐group study was conducted to evaluate the pharmacokinetics of the angiotensin II receptor antagonist irbesartan in subjects with varying degrees of renal function. Methods Forty subjects were divided into four treatment groups on the basis of 24‐hour cr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 1997-12, Vol.62 (6), p.610-618
Main Authors: Sica, Domenic A., Marino, Maria R., Hammett, Janice L., Ferreira, Irene, Gehr, Todd W. B., Ford, Neville F.
Format: Article
Language:English
Subjects:
Adult
Aged
Antihypertensive agents
Antihypertensive Agents - pharmacokinetics
Area Under Curve
Biological and medical sciences
Biphenyl Compounds - pharmacokinetics
Biphenyl Compounds - pharmacology
Cardiovascular system
Female
Humans
Kidney Failure, Chronic - metabolism
Male
Medical sciences
Metabolic Clearance Rate
Middle Aged
Pharmacology. Drug treatments
Renal Dialysis
Tetrazoles - pharmacokinetics
Tetrazoles - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose An open‐label, multiple‐dose, parallel‐group study was conducted to evaluate the pharmacokinetics of the angiotensin II receptor antagonist irbesartan in subjects with varying degrees of renal function. Methods Forty subjects were divided into four treatment groups on the basis of 24‐hour creatinine clearance (CLCR): normal renal function (> 75 ml/min/1.73 m2), mild to moderate renal impairment (30 to 74 ml/min/1.73 m2), severe renal impairment (
ISSN:0009-9236
1532-6535
DOI:10.1016/S0009-9236(97)90080-1